Financial Summary
January 1, 2021 - December 31, 2021
Third Quarter
January 1, 2021 - December 31, 2021 3rd Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2021 Second Quarter
（720KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2021 Second Quarter
（889KB）
-
Results Presentation Fiscal 2021 Second Quarter
（566KB）
-
Revenues from other products
（25KB）
-
Transcript of Results Briefing Fiscal 2021 Second Quarter (text)
（1,500KB）
First Quarter
January 1, 2020 - December 31, 2020
Fiscal Year
-
Consolidated Financial Summary Fiscal 2020
（601KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2020
（345KB）
-
Results Presentation Fiscal 2020
（448KB）
-
Summary of late-stage clinical trials
（566KB）
-
Revenues from other products
（25KB）
-
Transcript of FY 2020 Results/2021-2025 Medium Term Business Plan Briefing (text)
（2,712KB）
Third Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2020 Interim
（2,121KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2020 Interim
（573KB）
-
Results Presentation Fiscal 2020 Interim
（735KB）
-
Summary of clinical trials
（627KB）
-
Revenues from other products
（22KB）
-
Transcript of Results Presentation Fiscal 2020 Interim (text)
（1,274KB）
First Quarter
January 1, 2019 - December 31, 2019
Fiscal Year
-
Consolidated Financial Summary Fiscal 2019
（452KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019
（765KB）
-
Results Presentation Fiscal 2019
（1,045KB）
-
Summary of late-stage clinical trials
（187KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 (text)
（1,499KB）
Third Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2019 Interim
（251KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019 Interim
（490KB）
-
Results Presentation Fiscal 2019 Interim
（740KB）
-
Summary of late-stage clinical trials
（227KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 Interim (text)
（1,035KB）
First Quarter
IR Events
40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
-
Presentation material
（4,623KB）
-
Transcript (text)
（2,600KB）
- Presentation (webcast)
The webcast will be available until January 13, 2023.
Update on KHK4083
October 4, 2021 (Material added on November 5, 2021)
-
Pathogenesis and Latest Therapy of Atopic Dermatitis
（673KB）
-
EADV Follow-up
（456KB）
-
ISDS Presentation (Nov. 5 added)
（482KB）
-
Transcript (text)
（3,492KB）
| This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice. |
Kyowa Kirin ESG Briefing
September 8, 2021
-
ESG Briefing Presentation
（6,515KB）
-
Transcript (text)
（6,250KB）
Joint Development and Commercial Agreement of KHK4083 with Amgen
June 1, 2021
-
Presentation
（333KB）
-
Transcript (text)
（951KB）
- News Release
R&D Day
December 10, 2020
-
R&D Day Presentation
（1,406KB）
-
Transcript (text)
（2,871KB）
Updates on Nourianz marketing strategy in the U.S. and KW-6356 development
November 19, 2019
-
Agenda
（101KB）
-
2019 US NOURIANZ Commercial Update
（2,170KB）
-
A Phase 2a Study of KW-6356 in the Subjects with Parkinson's Disease
（1,398KB）
-
Transcript (text)
（2,086KB）
Update on KHK4083: A phase 1 study in subjects with atopic dermatitis
December 3, 2018
-
Agenda
（78KB）
-
A phase 1 study of KHK4083 in subjects with atopic dermatitis
（1,043KB）
Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU
October 27, 2017
IR News
-
December 24, 2021
Corporate Governance Report
（823KB）
-
November 01, 2021
Appendix to the Consolidated Financial Summary Fiscal 2021 Third Quarter
（868KB）
-
November 01, 2021
Consolidated Financial Summary Fiscal 2021 Third Quarter
（741KB）
-
August 03, 2021
Appendix to the Consolidated Financial Summary Fiscal 2021 Interim
（890KB）
-
August 03, 2021
Consolidated Financial Summary Fiscal 2021 Second Quarter
（720KB）
